SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is experiencing significant buzz following MSCI's decision not to exclude digital asset treasury companies from its indexes, dispelling a major bearish concern. This news is fueling anticipation of a substantial rally and short squeezes among bulls who believe the stock was undervalued, though some skeptics remain focused on potential dilution and Bitcoin's volatile price action.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is a major talking point as geopolitical focus intensifies on Greenland's strategic rare earth deposits, highlighted by U.S. administration comments. The community widely discusses the potential for government investment or partnership, viewing CRML's Tanbreez project as vital for Western supply chain independence from key mineral producing nations and speculating on substantial gains.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community eagerly anticipates the completion of its Northern Data acquisition, poised to significantly expand its AI and cloud capabilities. This move, coupled with substantial investment and service commitments from Tether, fuels widespread discussion about a potential short squeeze due to high short interest, alongside excitement for the imminent Rumble Wallet launch and the return of key content creators.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending after experiencing a sharp price drop, which many in the community attribute to competitive downgrades from Bank of America and Goldman Sachs following a recent equity offering. Investors are actively debating whether this is market manipulation by legacy institutions to acquire shares at a lower price, especially ahead of highly anticipated earnings and potential S&P 500 inclusion. Despite the decline, many view the dip as a strategic buying opportunity, confident in SoFi's long-term prospects as a fintech disruptor.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as market participants digest a major competitor's oral GLP-1 launch and its potential impact on pricing and competition. Community sentiment is sharply divided, with advocates highlighting VK2735's strong clinical profile and anticipating upcoming catalysts like the J.P. Morgan conference and FDA feedback on its oral program, while critics point to management's "go it alone" stance and recent insider share sales as causes for concern. This intense debate plays out against the backdrop of an expanding yet highly competitive obesity treatment landscape.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing immense investor interest, driven by the surging demand for memory and storage within the AI supercycle and reports of deepening industry shortages. The community is sharply divided, with bulls pointing to its market-leading momentum and short squeeze potential, while skeptics question the sustainability of its rapid ascent. This intense discussion reflects broader sector strength in AI infrastructure.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus (MNTS) is experiencing a surge following news of its innovative 3D-printed fuel tank, slated for flight testing on an upcoming SpaceX mission, igniting strong community interest in the aerospace sector. Investors are actively discussing its low float and high short interest, with many anticipating significant growth and comparing it to a "mini SpaceX" within the expanding space and defense industry.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending due to its recently executed agreement with the U.S. Department of Energy (DOE) for Project TETRA, a pilot reactor initiative to advance its Integral Molten Salt Reactor technology. The community views this as a significant validation, sparking comparisons to OKLO and intense discussion about IMSR's potential as a long-term player in meeting future energy demands, especially for AI infrastructure, amidst debates on its valuation and recent market performance.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is trending significantly following reports that Eli Lilly is nearing a deal to acquire the company for over $1 billion. This potential buyout has ignited widespread community discussion about the strategic value of Ventyx's oral inflammatory-disease drugs, especially its NLRP3 inhibitors, and their synergistic potential with major pharmaceutical pipelines. Many are actively speculating on the final acquisition price and the potential for a substantial short squeeze.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis Inc. is trending sharply after announcing overwhelmingly positive Phase 3 clinical trial results for its psoriasis drug, envudeucitinib, showcasing high efficacy and a favorable safety profile. The community is largely bullish, highlighting significant upside potential and revised analyst price targets due to the drug's 'best in class' data. However, there's also active discussion and speculation among traders regarding a proposed public offering and its potential short-term impact on the stock's trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Significant Decline in Short Interest

BioHarvest Sciences Inc. (NASDAQ:BHST - Get Free Report) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling...

BioHarvest Sciences (NASDAQ:BHST) Stock Price Down 5.1% - What's Next?

BioHarvest Sciences (NASDAQ:BHST) Stock Price Down 5.1% - Time to Sell...

BioHarvest Sciences (NASDAQ:BHST) Issues Earnings Results, Meets Expectations

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts...

BioHarvest Sciences Inc. (BHST) Reports Q3 Loss, Lags Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of 0.00% and -0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates

ABSCI CORP (ABSI) delivered earnings and revenue surprises of -5.26% and -79.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Inc. - Common Stock Earnings Preview

Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of +22.22% and -14.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +5.52% and +5.10%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Misses Revenue Estimates

BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -36.36% and -2.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

This account has been verified as an official BHST representative.

Verified Account

BioHarvest Sciences

BioHarvest Sciences, Inc. develops bio-cell growth platform technology. The firm engages in botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions. It offers nutraceutical health and wellness products, which includes dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients. The company was founded on April 19, 2013 and is headquartered in Vancouver, Canada.

BioHarvest Sciences Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$5.24
Prev Close	$5.41
Open	$5.16
Dividend Yield	0.00%
50-Day Moving Average	$6.77
Beta	-31.93
Avg. Volume	60,229.00
PE Ratio	-7.65

52-Week High	$12.80
52-Week Low	$4.72
Market Capitalization	$122.56M
EPS (Annual)	-$0.7974
Price to Book	13.29
Revenue Per Employee	$289,517.24
Enterprise Value/EBITDA	N/A

BHST
BioHarvest Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BHST News

BHSTBioHarvest Sciences Inc